NEW YORK (360Dx) – A team led by researchers at the German Cancer Research Center and Ruhr University Bochum has identified a blood-based marker that can identify patients likely to develop Alzheimer's disease more than a decade before the onset of symptoms.

The test measures the commonly used Alzheimer's protein biomarker amyloid-β (Aβ), but instead of measuring levels of different Aβ isoforms as is typically done, it looks for structural changes in Aβ indicative of the disease.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.